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Increasingly complex proteins can be made by a recombinant-chemical approach 
where proteins that can be made easily can be combined by site-specific chemical 
conjugation to form multifunctional or more active protein therapeutics. Protein 
dimers may display increased avidity for cell surface receptors. The increased size of 
protein dimers may also increase circulation times. Cytokines bind to cell surface 
receptors that dimerise, so much of the solvent accessible surface of a cytokine is 
involved in binding to its target. Interferon (IFN) homo-dimers (IFN-PEG-IFN) were 
prepared by two methods: site-specific bis-alkylation conjugation of PEG to the two 
thiols of a native disulfide or to two imidazoles on a histidine tag of two His8-tagged 
IFN (His8IFN). Several control conjugates were also prepared to assess the relative 
activity of these IFN homo-dimers. The His8IFN-PEG20-His8IFN obtained by histidine-
specific conjugation displayed marginally greater in vitro antiviral activity compared to 
the IFN-PEG20-IFN homo-dimer obtained by disulfide re-bridging conjugation. This 
result is consistent with previous observations in which enhanced retention of activity 
was made possible by conjugation to an N-terminal His-tag on the IFN. Comparison 
of the antiviral and antiproliferative activities of the two IFN homo-dimers prepared by 
disulfide re-bridging conjugation indicated that IFN-PEG10-IFN was more biologically 
active than IFN-PEG20-IFN. This result suggests that the size of PEG may influence 








As therapeutic proteins become more complex there is an opportunity to consider 
approaches that utilize site-specific conjugation technologies to link proteins that are 
easily made. Such a hybrid recombinant-chemical approach could in principle be 
used in a modular way to make a wide range of multifunctional proteins that would 
not be practical and cost-effective to make by recombinant technologies alone, 
especially in the early stage of development. An exclusively recombinant approach to 
make multifunctional therapeutic proteins requires that a polypeptide sequence must 
be used to link the two or more proteins together. As a non-natural sequence, the 
linking region may be immunogenic, so polypeptide linkers must be both functional 
and non-antigenic. As proteins become more complex, there is also often an 
increased propensity for aggregation and degradation during manufacture and 
storage1-2.  
Many proteins are structurally and functionally complex and form dimers3. 
Interferon (IFN) is a cytokine that was first described as an antiviral agent4. Type 1 
IFNs act on a target cell (not the virus) to inhibit replication and the lifecycle of a wide 
variety of viruses, thus conferring a state of resistance within the cell to viral 
infection5. There are a number of pharmaceutical forms of Type I IFNs, namely 
Infergen®, Intron A®, PegIntron® and Pegasys® for the treatment of viral diseases 
such as Hepatitis B and Hepatitis C6. IFN α-2b in the presence of zinc forms dimers 
that have been found to have similar crystal structures to interleukin-10 and IFN-γ, 
which interact with their receptors in the dimer form7-8.  
Site-specific protein modification technologies are required to link proteins 
together in a hybrid recombinant-chemical approach9-12 to make multifunctional 
proteins. There may be many therapeutic opportunities for multifunctional proteins2, 
13-15. Proteins linked together to be multivalent (for example, 16) or dimeric17-19 have 
been described using a range of modification technologies.  Dimerised proteins may 
increase avidity while also increasing solution size to prolong circulation times12, 20. 
Recombinant21 and chemical22-23 methods have been used to make different cytokine 
dimers2.  
Disulfide re-bridging conjugation is a site-specific method for protein 
modification that exploits the reactivity of the two thiols found in a native disulfide 
(Figure 1A)24-25. Mechanistically conjugation occurs by bis-alkylation by a sequence 
of addition-elimination reactions (Figure 1B). Interferon α2 has two disulfides, either 
of which can be readily conjugated (Figure 2).  
FIGURES 1-2 
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Disulfide re-bridging conjugation has also been used with reagents 
functionalized at each terminus of a PEG linker (e.g. PEG di(bis-sulfone) 4, Figure 
3B) to make bivalent IgG antibody mimetics called Fab-PEG-Fab (FpFs)26. FpFs are 
about the same size in solution as an IgG and can be made to be more stable in the 
hinge region. FpFs have been shown to be biologically active in vitro and in vivo with 
binding affinities comparable to IgGs targeted to the same epitopes27. Interestingly, 
FpFs display a propensity to have slower dissociation rates once bound to their 
target. Exploiting reduced dissociation rates may be a strategy to increase efficacy 
by retaining a therapeutic agent for a longer period of time within a target tissue28-29.  
Fc-fusion mimetics known as receptor-PEG-receptor (RpR) have also been 
prepared30. It was found that for an RpR targeted to vascular endothelial growth 
factor, that the RpR displayed a higher rate of association as well as a slower rate of 
disassociation. Together, these properties showed that a recombinant-chemical 
fusion protein mimetic can have higher affinity than a recombinant protein targeting 
the same epitope.   
IFN binds to two cell surface receptors that then dimerise, so much of the 
solvent accessible surface of IFN is involved in binding31.  Histidines are generally 
rare in proteins and contiguous histidines are only generally present in His-tags, 
which are widely used to simplify protein purification. In an effort to avoid modifying 
the IFN near a residue that may be involved in binding, IFN was made with an 8-
Histidine tag (His8-tag) at its N-terminus and then site-specifically mono- and di-
PEGylated by bis-alkylation using the PEG mono-sulfone 3 (Figure 3C)32. His-tag 
conjugation is thought to occur by a similar addition-elimination reaction (Figure 3D) 
that occurs with the two thiols from a disulfide bond.  
Following a recombinant-chemical approach to make IFN-α2 homo-dimers, 
activity of the IFN homo-dimer was determined. The cytokine was prepared 
recombinantly with an His8-tag at its N-terminal (His8IFN). PEG-di(mono-sulfone) 5 
(Figure 3B) was then used to make an IFN homo-dimer by histidine-specific 
conjugation (His8IFN-PEG-His8IFN). His8IFN was also used to make IFN-PEG-IFN by 
disulfide re-bridging conjugation using PEG di(bis)sulfone 4. Disulfide conjugation on 
His8IFN had not been conducted before this study. Mono-PEGylated and di-
PEGylated conjugates were also prepared as controls for comparison. PEG steric 
shielding should be at a maximum in the diPEGylated species (Figure 2) and the 
extent of PEG shielding was probed using a low molecular weight PEG (5 kDa) to 
make mono- and di-PEGylated IFN conjugates by disulfide re-bridging conjugation.     
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Materials and methods 
Preparation of PEG conjugation reagents 
PEG bis-sulfone reagents 1 were prepared as previously described25 using 
commercially available methoxy-terminated PEG mono-amine precursors of 5, 10 
and 20 kDa molecular weights.  The PEG di-(bis-sulfone) reagents were prepared as 
previously described26 and further purified by HPLC. Incubation of the PEG bis-
sulfone precursors (1 and 4) for 8 h (37°C) in 50 mM sodium phosphate buffer pH 7.4 
containing 150 mM sodium chloride provided PEG mono-sulfone 3 and PEG di-
(mono-sulfone) 5 for histidine-specific conjugation.  
His8IFN production 
The IFN α-2a (IFN) gene was designed to include eight histidines (His8) at the N-
terminus32. The DNA sequence was optimized using Gene Perfect software (Gene 
Oracle, Mountain View, California) and further optimized by manual removal of rare 
codons and repetitive sequences to remove double-strand RNA secondary structure. 
The Shuffle™ T7 Express E. coli bacterial strain with inserted plasmids containing 
the gene for the expression His8-IFN.  After fermentation and lysis, His8IFN was 
purified by immobilized metal affinity chromatography (IMAC) followed by fraction 
pooling and up purification by an anion exchange chromatography (AIEC, HiPrep™ Q 
FF 16/60 column).  Following SDS-PAGE analysis, the fractions containing pure 
His8IFN were pooled and the concentration measured by UV absorbance at 280 nm 
(ε=0.914, 0.9 mg/mL, 70 mL). The concentration was made to 0.5 mg/mL and the 
solution supplemented with 100 mM sodium chloride, 10% glycerol, protease 
inhibitor (dilution 1/5000), 1 mM EDTA and 1 mM sodium azide. His8IFN was then 
aliquoted into 5 mL cryovials and snap-frozen in liquid nitrogen and stored at -80°C.  
SDS-PAGE 
SDS-PAGE was conducted using 4-12% Bis-Tris polyacrylamide gels (NuPAGE®; 
NP0323BOX). Every gel was loaded with Novex® Sharp pre-stained standards 
(Novex; P/N 57318) and samples were loaded using an appropriately diluted 4×SDS 
sample buffer (NuPAGE®; NP0007). Gels were run in Xcell SureLock™ gel 
electrophoresis tanks (Invitrogen; EI0001) and run in MES SDS-PAGE running buffer 
(×20) from NuPAGE® (NP0002-02). Gels were stained using InstantBlue™ gel stain 
(Expedeon; ISB01L) and PEG stain (barium chloride and 0.05 M iodide were both 
from Fisher Scientific (B/0500/53; J/4410/15). Alternatively, silver stain 
(SilverXpress® Silver staining kit) was used from Invitrogen (LC6100). Densimetric 
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analysis was conducted using ImageQuant™ LAS 4010 instrument (GE Healthcare, 
28-9558-10). 
Determination of protein concentration 
MicroBCA™ Protein Assay Kit (Thermo Scientific, 23235) containing a solution of 
albumin standard (2 mg/mL) was diluted in an appropriate buffer (dependent on the 
sample buffer) to 200 µg/mL, 50 µg/mL, 25 µg/mL, 12.5 µg/mL, 6.25 µg/mL, 3.125 
µg/mL and 0 µg/mL (blank). The samples (75-150 µL) were incubated respectively 
with 75-150 µL MicroBCA™ solution (prepared by mixing solutions A:B:C in the 
ration of 25:24:1) at 37 ºC for 2 h. The absorbance was then measured (570 nm) to 
generate a standard curve. For His8IFN samples, appropriate dilutions (40-60 µg/mL) 
were made to a concentration within the linear part of the standard curve and the 
above steps followed. Additionally, for quantification of proteins in small volumes 
(<900 µL), Nanodrop 2000 spectrophotometer from Thermo Scientific (SPR-700-
310L) was used. 
Disulfide re-bridging conjugation; preparation of PEG-IFN-PEG, PEG2-IFN and 
PEG-IFN 
His8IFN (5 mg; 4.875 mL) in 50 mM sodium phosphate, 20 mM EDTA, pH 7.8 was 
reduced using DTT (1 M, 15.4 mg, 125 µL) for 30 min at RT, and the DTT was 
removed by buffer exchange using two pre-equilibrated PD-10 columns. The His8IFN 
concentration was quantified using UV at absorbance 280 nm (0.797 mg/mL, 6.5 mL) 
and was diluted to 0.5 mg/mL (10 mL). PEG20 bis-sulfone 1 was weighed (5.9 mg, 
1.2 eq.) and added to the reduced His8IFN (250 µL) in a 1:1 ratio (PEG20 bis-sulfone 
1:IFN). The PEG20-IFN reaction mixture was left for 3 h at RT, then 1 mM glutathione 
re-oxidising solution (GRS; 50 µL of 50 mM GSH:50 mM GSSG in 50 mM sodium 
acetate, pH 4.0) was added, and the reaction allowed to proceed for a further 16 h at 
20 ºC. SDS-PAGE analysis was conducted on the reaction mixture prior to cation 
exchange (IEX) purification using a 5 mL HiTrap Macrocap SP column connected to 
an ÄKTA prime which had been pre-equilibrated with buffer A (100 mM sodium 
acetate, pH 4.0). The protein conjugates were eluted with a step gradient of buffer B 
(1.0 M sodium chloride in 100 mM sodium acetate, pH 4.0) where the reaction 
mixture was loaded manually onto the column (ca. 10 mL), and the system was 
washed for 30 mL, then the gradient was initiated. Fractions containing the desired 
conjugates were combined and centrifugally concentrated using a VivaSpin column 
with 10,000 MWCO at 3000×g, 4ºC until ca. 1.5 mL remained. Once concentrated, 
the PEG20-IFN and PEG20-IFN-PEG20 conjugates were buffer exchanged into 50 mM 
sodium phosphate containing 20 mM EDTA, pH 7.8. Protein concentration was 
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estimated by measuring UV absorbance at 280 nm and was confirmed by MicroBCA 
assay for both PEG20-IFN and (PEG20)2-IFN conjugates (330 µg/mL and 147.5 
µg/mL, respectively). The yield for both PEG20-IFN and PEG20-IFN-PEG20 conjugates 
was 28.8% and 12%, respectively.  PEG10-IFN and PEG10-IFN-PEG10 were prepared 
similarly in yields of 14% and 16%, respectively.  PEG5-IFN and PEG5-IFN-PEG5 
were also prepared with yields of 29% and 34.5%, respectively. 
Preparation of PEG20-His8IFN and (PEG20)2-His8IFN  
PEG20 mono-sulfone 3 (0.502 mL, 2.5 eq.) was added to the His8IFN solution (2.837 
mL at 1.41 mg/mL) and incubated at 20ºC for 16 h. The reaction mixture was cooled 
to 4ºC and then incubated with sodium triacetoxyborohydride (50 mM) dissolved in 
DMSO at 4ºC for 1.5 h. The crude mixture (2×2.5 mL) was buffer exchanged into 100 
mM sodium acetate, pH 4.0, using a pre-equilibrated PD-10 desalting column. The 
reaction mixture was loaded into a 5 mL HiTrap Macrocap SP cation exchange 
column (CIEC, GE Healthcare; 28-9508-59) using an ÄKTA prime plus fitted with a 5 
mL loop which had been pre-equilibrated with buffer A (100 mM sodium acetate, pH 
4.0). The His8IFN species were eluted using a step gradient of buffer B (1.0 M 
sodium chloride in 100 mM sodium acetate, pH 4.0) with the following steps of 27%, 
36%, 55% and 100%, with each step eluting over six column volumes. Fractions (2 
mL) collected over the step gradient were then analyzed by SDS-PAGE and the 
desired conjugates were combined and concentrated using a VivaSpin column with 
10,000 MWCO at 3000×g, 4ºC, until the volume was approximately 1.5 mL. The 
PEG20-His8IFN and (PEG20)2-His8IFN conjugates were buffer exchanged into buffer A 
to decrease the salt concentration and enable the conjugates to bind to the column 
for a second CIEC purification cycle.  Protein concentration and yield was 
determined by measuring UV absorbance at 280 nm for both PEG20-His8IFN and 
(PEG20)2-His8IFN conjugates 1.054 mg (26%) and 0.483 mg (12%), respectively. UV 
absorbance at 280 nm and MicroBCA™ assay were conducted to quantify protein 
concentration after the second purification cycle and the final yields of PEG20-His8IFN 
and (PEG20)2-His8IFN conjugates were 0.7 mg (17.6%) and 0.29 mg (7.13%), 
respectively. 
Preparation of IFN dimer, His8IFN-PEG20-His8IFN by HIS-tag conjugation 
PEG20 di(mono)sulfone 5 (0.515 mL,1 eq.) was added to His8IFN solution (0.5 mL at 
3 mg/mL) and incubated for 16 h at 20ºC.  The reaction mixture was cooled to 4ºC 
and then incubated with sodium triacetoxyborohydride (100 mM) dissolved in DMSO 
at 4ºC for 1.5 h. The crude mixture was then buffer exchanged into 100 mM sodium 
acetate, pH 4.0, using a pre-equilibrated PD-10 desalting column. The reaction 
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mixture was then loaded into a 5 mL HiTrap Macrocap SP CIEC column using an 
ÄKTA prime plus fitted with a 5 mL loop which had been pre-equilibrated with buffer 
A (100 mM sodium acetate, pH 4.0). A buffer B (1 M sodium chloride, 100 mM 
sodium acetate, pH 4.0) step gradient of 27%, 36%, 55%, 80% and 100% was used 
to elute the different His8IFN species. Fractions containing His8IFN-PEG20-His8IFN 
were combined and concentrated using a VivaSpin column with 10,000 MWCO at 
3000×g, 4ºC, until the volume was approximately 1.5 mL. The conjugate solution was 
buffer exchanged into 50 mM sodium phosphate containing 150 mM sodium chloride, 
pH 7.4 and the protein concentration and yield was measured by UV at 280 nm for 
His8IFN-PEG20-His8IFN to be 0.407 mg/mL (13.5%) yield. SEC was used to separate 
His8IFN-PEG20-His8IFN from trace amount of unmodified His8IFN. The mixture was 
loaded into a 120 mL Superdex™ 200 prep grade column 16/60 using an ÄKTA prime 
plus fitted with a 2 mL loop which had been pre-equilibrated with 50 mM sodium 
phosphate containing 150 mM sodium chloride, pH 7.4. Collected fractions were 
analyzed by SDS-PAGE and visualized with silver stain, and the purest fractions of 
His8IFN-PEG20-His8IFN were combined and concentrated using pre-equilibrated 
VivaSpin column with 10,000 MWCO at 3000×g, 4ºC, until  approximately 1.5 mL 
remained. The His8IFN-PEG20-His8IFN concentration and yield (0.030 mg/mL, 1.5%) 
was measured by UV at 280 nm and MicroBCA assay.  
Preparation of IFN dimer, IFN-PEG-IFN by disulfide re-bridging conjugation 
His8IFN (2 mg/mL, 5 mL) in 50 mM sodium phosphate 20 mM EDTA, pH 7.8, was 
reduced using DTT (1 M, 15.4 mg, 125 µL) for 30 min at RT, and the DTT was 
removed by buffer exchange using three pre-equilibrated PD-10 columns. Protein 
concentration was quantified by UV at 280 nm (0.752 mg/mL, 11 mL) and His8IFN 
was diluted to 0.5 mg/mL (15 mL), where one half (7.5 mL, 4.1 mg) of this reduced 
His8IFN was used to prepare IFN-PEG10-IFN and the other half used to prepare IFN-
PEG20-IFN.  For IFN-PEG20-IFN, PEG20 di(bis)sulfone 4 (2.5 mg) was added to the 
solution of reduced His8IFN (106 µL) in a 2:1 ratio (PEG20 di(bis)sulfone 4:IFN). The 
reaction mixture was left for 5 h at 20ºC, then GRS (1 mM, 153.1 µL of 50 mM 
GSH:50 mM GSSG in 50 mM sodium acetate, pH 4.0) was added, and the reaction 
was allowed to proceed for a further 16 h at 20ºC. SDS-PAGE analysis was 
conducted on the reaction mixture prior to and after GRS addition. The IFN-PEG20-
IFN conjugate was then incubated with sodium triacetoxyborohydride (100 mM 
dissolved in DMSO) at 4ºC for 1.5 h. The reaction mixture (7.5 mL) was then buffer 
exchanged into 100 mM sodium acetate, pH 4.0, using three pre-equilibrated PD-10 
desalting columns.  CIEC purification was conducted with a 5 mL Macrocap SP ion 
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exchange column using an ÄKTA Prime Plus fitted with two 5 mL loops which had 
been pre-equilibrated with buffer A (100 mM sodium acetate, pH 4.0). The protein 
conjugates were eluted with a step gradient of buffer B: 1.0 M sodium chloride in 100 
mM sodium acetate, pH 4.0, of 45%, 55% and 100%.  
IFN-PEG10-IFN and His8IFN mixtures were separately combined and 
concentrated using a VivaSpin column with 10,000 MWCO at 3000×g, 4ºC until 
approximately 1.5 mL remained. The mixtures were buffer exchanged using pre-
equilibrated NAP-10 columns into 50 mM sodium phosphate containing 150 mM 
sodium chloride, pH 7.8. Protein concentration and yield was calculated by 
measuring UV at 280 nm for both IFN-PEG20-IFN + His8IFN, IFN-PEG10-IFN + 
His8IFN mixtures (0.682 mg/mL, 27.3% and 1.12 mg/mL, 27.3%, respectively).  
SEC purification of IFN-PEG20-IFN + His8IFN and IFN-PEG10-IFN + His8IFN 
mixtures was performed to separate His8IFN from IFN-PEG20-IFN and IFN-PEG10-
IFN. The mixtures were loaded separately onto the Superdex 200 Prep Grade 
Column 16/60 120 mL column, which had been pre-equilibrated with 50 mM sodium 
phosphate containing 20 mM EDTA, pH 7.8, using an ÄKTA Prime Plus fitted with a 
2 mL loop. The protein conjugates were eluted over 120 mL and the fractions 
collected were then analyzed by SDS-PAGE and stained using silver stain. Fractions 
were combined and concentrated using a VivaSpin column with 10,000 MWCO at 
3000×g, 4ºC until approximately 1.5 mL remained. Protein concentration for both 
IFN-PEG20-IFN and IFN-PEG10-IFN were measured by UV at 280 nm and confirmed 
by MicroBCA assay to 0.035 and 0.046 mg/mL, respectively. Final yields for IFN-
PEG20-IFN and IFN-PEG10-IFN conjugates were 1.4% and 1.12%, respectively.  
Assessment of conjugate stability 
Samples were incubated at 4ºC for 7 days and monitored by SDS-PAGE with the 
resulting gels stained by InstantBlue™ and PEG stain. For conjugated proteins with a 
low concentration, silver stain was used to detect the conjugate and any free protein. 
Accelerated stability assessments were conducted by first buffer exchanging 
samples into 10 mM ammonium bicarbonate, pH 8.0, and protein concentrations 
were diluted to 50 µg/mL, and then 27 µL was transferred into 4×0.5 mL sample 
vials.  For each protein product, two of the sample vials were made up to 30 µL with 
the addition of 3 µL of 10 mM ammonium bicarbonate, pH 8.0, while the two 
remaining sample vials are made up to 30 µL with 100 mM DTT solution. For each 
protein product, two sample vials (one with DTT and one without) were heated on a 
metal heating block to 90ºC for 10 min. The two remaining sample vials (one with 
DTT and one without) were then heated in the metal heating block for 1 h at 50ºC. 
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Once all sample vials for each protein product were cooled to RT, 22 µL was 
removed from each sample vial and transferred into new labeled sample vials 
containing loading dye (11 µL). The sample/loading dye mixtures were subsequently 
analyzed by SDS-PAGE and stained with InstantBlue™ and PEG stain, to identify if 
the protein conjugates underwent de-conjugation as determined by the presence of 
unmodified His8IFN.  
Antiviral potency assay 
The human lung fibroblast A549 cell line (HPACC; 86012804) was maintained in 
Dulbecco’s Modified Eagles medium (DMEM) (Gibco/Fisher Scientific; VX21969035) 
supplemented with 10% Fetal Bovine Serum (FBS) (Gibco/Fisher Scientific; 
VX25030024), 50 units/mL penicillin (PAA; P11-101), 2 mM L-glutamine (Sigma; 
G7513-100 mL) and 50 µg/mL streptomycin. A549 cells were infected using 
encephalomyocarditis virus (EMCV) (ATCC; VR-129B). Sample controls were NIBSC 
IFN standard (HPACC; 95/650) and Pegasys® (Roche). Phosphate buffered saline 
(PBS), pH 7.4 (BPE399-20); formaldehyde (40%) (F/145/PB17) and SDS (10%) 
(BPE 2436-1) were supplied from Fisher Scientific. Methyl violet 2B was from Sigma 
Aldrich (198099). Microplate reader was supplied from Dynex Technologies/Opsys 
MR and the microplate shaker was supplied from VWR (444-7094). To conduct the 
antiviral assay, A549 cells were plated (1.7×105 cells/mL at 50 µL/well) in 96 well flat-
bottomed tissue culture plates, then incubated at 37ºC, 5% CO2, overnight until the 
cells were 80% confluent. Serial dilutions (2-fold) of the IFN samples were prepared 
in DMEM/10% FBS in 96 well V-bottom plates and diluted samples (50 µL) were 
transferred to flat-bottom plates and incubated for 24 h at 37ºC, 5% CO2. Protein 
samples were tested in triplicate and control wells contained only cells (negative 
control) or cells with virus (positive control). After incubation, the protein sample and 
media were discarded and EMCV (50 µL), pre-titrated to achieve complete killing in 
24 h in control wells, was added to all wells except for the negative control wells 
where, 50 µL/well of DMEM/2% FBS was added. The plate was then incubated for 
21 h at 37ºC after which ca. 80% cell death occurred in the control wells. Media was 
then discarded and the wells were washed with 300 µL/well of PBS added. Plates 
were then incubated for 30 min at RT with 50 µL/well of 4% formaldehyde/0.5% 
methyl violet. After incubation, the plates were washed twice with PBS (200 µL/well) 
and tap-dried. Dye was solubilized by 20 min agitation in 50 µL/well of 2% SDS and 
the absorbance measured at 570 nm. 
The interferon concentration (the log reciprocal of the interferon dilution) was 
plotted against the absorbance achieved and the reduction in cell viability was fitted 
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to a sigmoidal dose-response curve.  Data was only considered valid under two 
criteria, i) the variation between the straight part of the sigmoidal curve and the data 
points was small enough to be accurately represented by a straight line (absolute 
sum of squares (r value)) and ii) the ED50 for the internal control, NIBSC IFN α, was 
within the expected range. If the data achieved was not in line with this criterion, the 
data were not used. Accepted potency data was then turned into international units 
(IU) to allow for direct comparisons to be made with data described in the literature. 
GraphPad Prism 5 was used for all data analysis. 
Antiproliferative assay  
The human Negroid Burkitt’s lymphoma Daudi cell line (HPACC, 85011437) was 
maintained in RPMI 1640 media supplemented with 10% FBS, 50 units/mL penicillin 
and 50 µg/mL streptomycin. Daudi cells were plated (1.7×105 cells/mL at 100 µL/well) 
in a 96 well round-bottomed tissue culture plates and these were incubated at 37ºC, 
5% CO2. Serial dilutions (three-fold) of IFN α controls (NIBSC IFN and Pegasys®) 
were conducted in 1.5 mL centrifuge tubes using RPMI 1640/10% FBS. IFN controls 
were pipetted into the plate (100 µL/well) from low to high dilutions in duplicate, with 
each well having a final volume of 200 µL/well. Control wells contained only media 
without cells (negative control) or cells with media (as positive control). The plates 
were incubated for 72 h at 37ºC, 5% CO2. Methyl thiazolyl tetrazolium (MTT, 5 
mg/mL, Sigma) was dissolved in PBS and was prepared 10 min before addition to 
the wells. MTT solution was filtered through a 0.2 µm syringe filter and then added 
(20 µL) to each well and the plates incubated for 3 h at 37ºC, 5% CO2. Plates were 
then centrifuged at 1500×g for 10 min, allowing formazan crystals to sediment. Using 
a multichannel pipette, the supernatant was carefully removed and 100 µL/well non-
sterile DMSO was added to solubilize the crystals by agitation. Absorbance was then 
measured at 570 nm. Cell viability (%) was plotted against control wells using site-
specific binding with Hill slope on a semi-log graph (GraphPad Prism 5). The 
interferon concentration (the log reciprocal of the interferon dilution) was plotted 
against the absorbance achieved and the reduction in cell viability was fitted to a 
sigmoidal dose-response curve. Data was only accepted if the variation between the 
straight part of the sigmoidal curve and the data points was small enough to be 
accurately represented by a straight line (absolute sum of squares (r value)). 
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Results and Discussion 
Reagent synthesis. 
Terminally functionalized PEG di(bis-sulfones) 4 (Figure 3B) capable of bis-alkylation 
conjugation at each PEG terminus were prepared using commercially available 10 
and 20 kDa PEG diamines (NH2-PEG-NH2)26 and the precursor bis-sulfone linker25. 
Likewise the, PEG bis-sulfones 1 were prepared from commercially available 5, 10 
and 20 kDa PEG amine25. The mono-sulfone adducts (3 and 5) were obtained by 
elimination of toluene sulfinic acid 224.   
FIGURE 3 
Preparation of His8IFN 
Recombinant IFN α-2a fused with an eight-histidine tag (His8) was prepared by using 
the SHuffle™ T7 expression system which can correctly produce disulfide containing 
proteins in high yields within the cytoplasm of E. coli33. The His8-tag was attached 
between the cysteine and methionine at the N-terminus end of IFN32. Lysis was 
conducted firstly by sonication and then cross flow-filtration to remove the soluble 
His8IFN from the cell debris. As His8IFN was expressed as a soluble protein, 
purification was conducted at physiological pH to maintain the stability and activity of 
the protein. His8IFN was purified in two steps, first using immobilized metal affinity 
chromatography (IMAC) taking advantage of the presence of the His8-tag. His8IFN 
was then eluted over an anion exchange column (AIEC).   
The identity of pure His8IFN (Figure 4A) was confirmed by Western blot 
(Figure 4B). His8IFN was prepared two times in 500 mL cultures with a final yield 
after purification of between 60-70 mg. His8IFN was stored in small vials at -80ºC 
(0.5 mg/mL) for conjugation reactions. The biological potency of His8IFN was 
assessed in vitro by the prevention of infection of A549 cells by EMCV34.  The 
His8IFN displayed a specific activity of 231 ± 10.95 MIU/mg, whilst the positive control 
of NIBSC (non-his-tagged) IFN α-2a displayed an activity of 254 MIU/mg. In literature 
His8IFN has been reported to display an ED50 of 7 pg/mL32. The activity of non-his-
tagged interferon α2 is reported to be 1.4×108 IU/mg. 
FIGURE 4 
Preparation of the His8IFN-PEG20-His8IFN homo-dimer by histidine-specific 
conjugation 
The IFN-PEG-IFN homo-dimer (His8IFN-PEG20-His8IFN) derived from histidine-
specific conjugation was achieved using PEG20 di-(mono-sulfone) 5 (1 eq. in 200 mM 
sodium phosphate containing 150 mM sodium chloride) and three molar equivalents 
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of His8IFN (3.3 mg/mL, 0.5 mL in 50 mM sodium acetate, pH 5.3, containing 35 µM 
hydroquinone). Histidine-specific conjugation generally requires a slightly acidic pH 
to maintain site-selectivity, so use of the mono-sulfone reagents (3 and 5) is one way 
to better target the His8-tag on the IFN. The reaction mixture was incubated for 16 h 
at 20ºC at approximately pH 6.5 and then treated with 100 mM sodium tri-acetoxy-
borohydride (STAB) to reduce the electron-withdrawing carbonyl to prevent retro-
Michael reactions. A band at 70-80 kDa in the SDS-PAGE was consistent for the 
formation of His8IFN-PEG20-His8IFN. The molecular weight of each IFN is ca. 20 kDa 
(2×20 kDa = 40 kDa) and PEG often migrates in SDS-PAGE to about twice the 
molecular weight of the protein standards.   
However, SDS-PAGE analysis showed that conversion was low with a 
significant amount of unconjugated IFN still present in the reaction mixture. Since the 
goal was to isolate the IFN homo-dimer, the reaction mixture was subjected to 
purification by CIEX. The His8IFN-PEG20-His8IFN dimer was separated from the 
unconjugated PEG species (Figure 5A, lane 3), but the desired His8IFN-PEG20-
His8IFN dimer could not be separated from other high molecular weight IFN 
impurities even after a second purification by CIEX (Figure 5A, lane 4).  
FIGURE 5 
The conjugation was repeated and a single CIEX purification was conducted 
followed by purification of the fractions containing His8IFN-PEG20-His8IFN by SEC to 
remove the high molecular weight species (Figure 5A, lane 5). An anti-IFN Western 
blot was conducted to confirm the presence of IFN (Figure 5A, lane 6) in the purified 
His8IFN-PEG20-His8IFN. 
The final yield of His8IFN-PEG20-His8IFN homo-dimer after one cycle of IEX 
followed by one cycle of SEC purification was 1.5% (Table 1) based on UV and 
MicroBCA™ assays. PEG20-His8IFN and (PEG20)2-His8IFN were prepared using the 
PEG mono-sulfone 3. Good purification of these modified proteins was accomplished 
using two IEX steps and the purified conjugates were isolated in 17.6% (0.7 mg) and 
7.1 % (0.29 mg) yields, respectively (Figure 5B, Lanes 3-4, Table 1). 
TABLE 1 
The purified His8IFN-PEG20-His8IFN was stored at 4°C for 2 months (50 mM 
sodium phosphate containing 150 mM sodium chloride, pH 7.8). No free His8IFN was 
observed in the SDS PAGE using silver stain, indicating there was no de-
conjugation. Conjugate stability for His8IFN-PEG20-His8IFN was also evaluated at 
50ºC and 90°C in the presence and absence of DTT (Figure 5C). No free His8IFN 
was observed. The imidazole side chain of histidine is a weaker nucleophile than free 
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thiol. Since conjugate formation occurs via a reaction mechanism that involves a 
sequence of equilibria (Figure 3D), it was important to ensure that bonds formed 
between the His8-tag and the PEG di-(mono-sulfone) 5 had been stabilized by the 
treatment with STAB to reduce the electron-withdrawing carbonyl in the reagent after 
conjugation. Both PEG20-His8IFN and (PEG20)2-His8IFN conjugates that were also 
prepared in this study were evaluated at 50ºC and 90°C in the presence and 
absence of DTT (Figure 5D).  No de-conjugation was observed for either of these 
conjugates. 
Preparation of IFN-PEG-IFN homo-dimers by disulfide re-bridging conjugation 
Conjugation of the disulfide thiols has not previously been conducted on His8IFN. 
Once the IFN thiols are liberated after disulfide reduction, thiol addition to the PEG 
bis-sulfone reagents (1 and 4) is much more favored compared to the addition 
reaction of the imidazole side-chain of histidine. IFN has two accessible disulfides 
and IFN maintains its tertiary structure in the presence of DTT after reduction of the 
disulfides35.   
Bis-alkylation conjugation of His8IFN was first conducted using PEG bis-
sulfone 1 (5, 10 and 20 kDa) to prepare the corresponding PEG-IFN and PEG2-IFN 
conjugates (Figure 6A, lanes 3-8, Table 1).  These conjugates were isolated from the 
same reaction mixture using 1 molar equivalent of PEG bis-sulfone 1 to protein, and 
the PEG2-IFN conjugate was easily isolated as a co-product. The conjugation 
conversion and the purification process comprising a single CIEX for the His8IFN-
derived conjugates is similar to what has been observed with IFN36 that does not 
possess a His-tag.   
FIGURE 6 
The IFN-PEG-IFN homo-dimers were prepared using a 2:1 molar ratio of 
His8IFN to PEG di(bis)sulfone 4 (10 and 20 kDa reagents). His8IFN was reduced 
using 20 mM DTT and then the protein was buffer exchanged into 50 mM sodium 
phosphate 20 mM EDTA. A pH of 7.8 was used because the PEG di(bis)sulfone 4 
readily undergoes elimination of the toluene sulfinic acid 2 (Figure 3B) to generate 
the PEG di-(mono-sulfone) 5 in situ followed by the Michael reaction of free protein 
thiols. Reduced His8IFN (0.5 mg/mL, 7.5 mL) was allowed to incubate for 5 h at 20ºC 
separately with the 10 kDa and 20 kDa PEG di(bis-sulfone)s 4. To re-oxidise the 
unconjugated thiols of the remaining disulfide, a glutathione re-oxidising solution 
(GRS) was added (50 mM, 153 µL) and the reaction mixture was allowed to incubate 
a further 16 h at 20ºC before being treated with STAB to reduce the electron-
withdrawing carbonyl to prevent retro-Michael reactions.  
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Purification of the two IFN-PEG-IFN homo-dimers was accomplished by CIEX 
followed SEC (Figure 6A, lanes 9 and 10). SEC was required to purify the desired 
IFN homo-dimer from the starting His8IFN which could not be separated by CIEX. 
Anti-IFN Western blots substantiated the presence of IFN in the homo-dimers while, 
importantly, confirming the absence of the starting His8IFN in the purified products.  
UV and BCA quantification was conducted and the yields obtained for the 
purified IFN-PEG20-IFN and IFN-PEG10-IFN were 0.85% (35 µg/mL) and 1.1% (46 
µg/mL), respectively. As with the IFN homo-dimer derived from histidine-specific 
conjugation (His8IFN-PEG20-His8IFN), the isolated yields for the purified IFN homo-
dimers were low. Clearly the SEC purification step is not optimal for a purification 
process, since SEC can result in reduced yields for small scale reactions. The 
reaction was repeated to make both the 10 and 20 kDa IFN homo-dimers, but the 
yields were not improved.  
Storage of the disulfide re-bridged conjugates in 50 mM sodium phosphate, 
150 mM NaCl, pH 7.8, for 7 days at 4ºC did not show any evidence of de-conjugation 
(Figure 6B). Accelerated stability studies were also performed by incubating the IFN 
homo-dimers and their mono-PEGylated variants (ca. 40 µg/mL) at 90ºC (10 min) 
with or without 20 mM DTT (Figure 6C-D). No free His8IFN was observed indicating 
that there was no de-conjugation of the IFN from the PEG-linker.  
In vitro potency of IFN homodimers 
IFN is a pleiotropic cytokine that has numerous distinct biological properties; one of 
these is antiviral activity. This can be assessed in vitro, by the prevention of infection 
of A549 cells by EMCV34.  The relative activity of the IFN homo-dimers and PEG-IFN 
conjugates was determined by comparing the dose (concentration) of the sample, 
which displays 50% prevention of infection in cells or (50% effective dose or ED50) in 
vitro to the dose of the National Institute for Biological Standards and Control 
(NIBSC) reference standard IFN α-2a. The ED50 was then used to calculate the 
specific activity of each His8IFN conjugate. In addition to the NIBSC IFN control, 
Pegasys® was also used. Pegasys ® is a 40 kDa branched PEG-IFN α-2a conjugate 
that is a marketed product for the treatment of hepatitis C.  
The IFN homo-dimers retained activity that was comparable or better than 
Pegasys ® (Figure 7A-B and Table1).  Both PEG20-derived homo-dimers (His8IFN-
PEG20-His8IFN and IFN-PEG20-IFN) displayed less activity than the corresponding 
mono-PEGylated species, but more activity than the corresponding di-PEGylated 
species. However, the IFN homo-dimer IFN-PEG10-IFN did retain more activity than 
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the corresponding PEG10-IFN mono-PEGylated conjugate (Figure 7B, Table 1), 
suggesting there could be a dependency on PEG size linking the two IFNs.  
FIGURE 7 
 The histidine-specific mono-PEGylated conjugate (PEG20-His8IFN) displayed 
greater retained activity compared to the disulfide re-bridged mono-PEGylated 
conjugates, PEG10-IFN and PEG20-IFN (Table 1). This is consistent with a previous 
study for the PEGylating IFN at the N-terminal His-tag32.  When comparing the two 
PEG20-derived homo-dimers, the histidine-specific homo-dimer (His8IFN-PEG20-
His8IFN) also displayed more activity than the IFN-PEG20-IFN dimer.   
Due to the site specificity of the disulfide re-bridging PEGylation, the activity 
of PEG10-IFN and PEG20-IFN were comparable as previously reported24.  
Interestingly, the PEG5-IFN conjugate displayed considerably more activity than any 
of the higher molecular weight PEG-IFN conjugates (Figure 7 and Table 1), 
suggesting that when PEG5 is site-specifically conjugated by disulfide re-bridging 
conjugation, this molecular weight of PEG is below a steric shielding threshold at 
these sites of conjugation.   
An antiproliferative assay using Daudi cells was conducted, but due to the 
large quantity of sample required, only the disulfide re-bridged mono-PEGylated and 
IFN homo-dimers were evaluated. As with the antiviral assay, the PEG10 homo-dimer 
(IFN-PEG10-IFN, 1.52 ± 0.47 MIU/mg) again displayed higher activity than the PEG20 
homo-dimer (IFN-PEG20-IFN, 0.81 ± 0.09 MIU/mg). The activity of the starting 
His8IFN in this assay was 329.36 ± 87.98 MIU/mg. 
Conclusion 
Interferon (IFN) homo-dimers were prepared by site-specific bis-alkylation 
conjugation of IFN.  PEG (10 and 20 kDa) di-functionalized linkers were used to 
conjugate two IFN molecules to the two PEG termini. Both histidine-specific and 
disulfide re-bridging conjugation processes were examined to isolate the purified the 
IFN homo-dimers. The His8IFN-PEG20-His8IFN obtained by histidine-specific 
conjugation displayed marginally greater in vitro antiviral activity than the IFN-PEG20-
IFN homo-dimer obtained by disulfide re-bridging conjugation. This result is 
consistent with previous observations in which enhanced retention of activity was 
made possible by conjugation to an N-terminal His-tag on the IFN. Comparison of the 
antiviral and antiproliferative activities of the two IFN homo-dimers prepared by 
disulfide re-bridging conjugation indicated that IFN-PEG10-IFN was more biologically 
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active than IFN-PEG20-IFN. This result suggests that the size of PEG may influence 
the antiviral activity of IFN-PEG-IFN homo-dimers. 
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Figure 1. (A) Disulfide re-bridging conjugation is a site-specific strategy for modifying proteins 
by bis-alkylation where a native disulfide is linked with a three-carbon bridge that is bound to 
PEG.  (B) Bis-alkylation conjugation occurs by a sequence of addition and elimination steps 





Figure 2.  The range of interferon-α2 (IFN) conjugates that can be accomplished by disulfide 
re-bridging conjugation at either of the two disulfides in IFN (Cys1-98 or Cys29-Cys138). 
Reagents that are functionalized at each PEG terminus can be used to prepare IFN homo-
dimers (IFN-PEG-IFN).  IFN can also be prepared with a His-tag (His8 in this study) at the N-









Figure 3. (A) PEG bis-sulfone 1 undergoes elimination of toluene sulfinic acid 2 leaving group 
to generate the PEG mono-sulfone 3 that undergoes bis-alkylation conjugation with a protein.  
(B) PEG linkers can be functionalized at each terminus to give the corresponding PEG di(bis-
sulfone) 4 which can undergo elimination to generate the PEG di(mono-sulfone) 5 that can 
undergo site-specific conjugation to two proteins. (C) A protein His-tag can also be a target 
for bis-alkylation conjugation. (D) Bis-alkylation conjugation to a His-tag occurs by a similar 
set of addition and elimination reactions, which occur for two thiols in a reduced disulfide. 







Figure 4.  Characterisation of the final His8IFN product by (A) SDS-PAGE (n=2) 
(InstantBlue™ stain), Lane 1: Novex pre-stained markers and Lane 2: purified His8IFN. (B) 







Figure 5. (A) SDS-PAGE (silver stain) of CIEX purified His8IFN-PEG20-His8IFN. Lane 1: 
Novex pre-stained markers, Lane 2: His8IFN α-2a, Lane 3: one pass CIEX purified His8IFN-
PEG20-His8IFN, Lane 4: two-step CIEX purified His8IFN-PEG20-His8IFN. Lane 5: His8IFN-
PEG20-His8IFN after one CIEX and one SEC step and Lane 6: Anti-IFN Western blot of 
His8IFN-PEG20-His8IFN. (B) SDS-PAGE (InstantBlue™ and PEG stain) of final PEG20-His8IFN 
and (PEG20)2-His8IFN, Lane 1: Novex pre-stained markers, Lane 2: His8IFN, Lane 3: PEG20-
His8IFN, Lane 4: (PEG20)2-His8IFN. (C) SDS-PAGE (InstantBlue™ and PEG stain) analysis of 
His8IFN-PEG20-His8IFN homo-dimer incubated ± DTT at 50ºC and 90ºC, Lane 1: Novex pre-
stained markers, Lane 2: -DTT 50ºC, Lane 3: +DTT 50ºC, Lane 4: -DTT 90ºC, Lane 5: +DTT 
90ºC. (D) SDS-PAGE (InstantBlue™ and PEG stain) analysis of PEG20-His8IFN (Lanes 6-9) 
and (PEG20)2-His8IFN (Lanes 2-5) stressed with ± DTT at 50ºC and 90ºC. His8IFN-PEG20-








Figure 6.  (A) SDS-PAGE analysis of the conjugates prepared by disulfide re-bridging 
conjugation of His8IFN (InstantBlue™ and PEG stain) Lane 1: Novex pre-stained markers, 
Lane 2: His8IFN, Lane 3: PEG20-IFN, Lane 4: (PEG20)2-IFN, Lane 5: PEG10-IFN, Lane 6: 
(PEG10)2-IFN, Lane 7: PEG5-IFN, Lane 8: (PEG5)2-IFN. Lane 9: IFN-PEG20-IFN, Lane 10: 
IFN-PEG10-IFN, Lanes 11 and 12: Anti-IFN Western blot of IFN-PEG20-IFN and IFN-PEG10-
IFN. (B) Thiol conjugated IFN conjugates incubated at 4ºC for 7 days. Lane 1: Novex pre-
stained markers, Lane 2: His8IFN, Lane 3: PEG20-IFN, Lane 4: (PEG20)2-IFN, Lane 5: PEG10-
IFN, Lane 6: (PEG10)2-IFN, Lane 7: PEG5-IFN, Lane 8: (PEG5)2-IFN, Lane 9: IFN-PEG20-IFN, 
Lane 10: IFN-PEG10-IFN. No evidence of free or aggregated protein was observed by SDS-
PAGE analysis using InstantBlue™ and PEG stain. (C and D) SDS-PAGE (silver stain) 
analysis of disulfide-conjugated IFN conjugates stressed with ± DTT for 10 min at 90ºC. (C) 
Lane 1: Novex pre-stained markers, Lane 2: IFN-PEG10-IFN -DTT, Lane 3: IFN-PEG10-IFN 
+DTT, Lane 4: PEG10-IFN -DTT, Lane 5: PEG10-IFN +DTT. (D) Lane 1: Novex pre-stained 
markers, Lane 2: IFN-PEG20-IFN -DTT, Lane 3: IFN-PEG20-IFN +DTT, Lane 4: PEG20-IFN -
DTT, Lane 5: PEG20-IFN +DTT.  The disulfide re-bridged conjugates were found to be stable 







Figure 7. In vitro antiviral activity of conjugates with A549 cells incubated with EMCV 
virus. (A) His8-tag modified conjugate and (B) disulfide re-bridged conjugates with 
the left hand axis to be used for the starting His8IFN only. The right hand y-axis is 












Work-up Yield (%) 
Specific activity 
(MIU/mg) (n) 
1 His8IFN  - - 231.31 ± 10.95 (3) 
2 Pegasys® - - 2.43 ± 0.06 (3) 
3 His8IFN-PEG-20-His8IFN IEX, SEC 1-2 5.78 ± 1.62 (2) 
4 (PEG20)2-His8IFN 2× IEX 7 0.38 ± 0.16 (3) 
5 PEG20-His8IFN 2× IEX 18 9.84 ± 2.08 (3) 
6 IFN-PEG20-IFN IEX, SEC 1 2.12 ± 0.64 (4) 
7 PEG20-IFN IEX 29 3.95 ± 1.69 (5) 
8 (PEG20)2-IFN IEX 12 0.55 ± 0.04 (3) 
9 IFN-PEG10-IFN IEX, SEC 1 5.99 ± 2.08 (4) 
10 PEG10-IFN IEX 14 4.86 ± 1.77 (5) 
11 (PEG10)2-IFN IEX 16 0.12 ± 0.04 (3) 
12 PEG5-IFN IEX 29 51.89 ± 10.45 (2) 
13 (PEG5)2-IFN IEX 35 0.84 ± 0.03 (3) 
 
Table 1.  Summary of purification, yield and specific activities achieved for the IFN-
PEG-IFN homo-dimers (in red) and the controls that were prepared. Grey shading 
used to indicate the His8-tag conjugated species that were prepared. The remaining 
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